Drug intelligence / Profile preview

Beta-3-Cysteine

Development stage: Unknown
Modality: Small Molecules

Overview

Beta-3-Cysteine is a small molecule drug with the molecular formula C4H9NO2S and a molecular weight of 135.19 g/mol. It is identified as a small molecule drug that targets ENV_HV1BN. Its development phase and specific therapeutic indications are currently unknown.

Other names: (3R)-3-amino-4-sulfanylbutanoic acid

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on Beta-3-Cysteine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-3-Cysteine.

Explore the full profile